Merck gets FDA nod for Janumet

The FDA approved Merck combination pill Janumet, for type 2 diabetes. The drug contains Merck’s sitagliptin—the active ingredient in Januvia—and an older glucose-lowering agent called metformin. Januvia, part of a class of drugs called DPP-4 inhibitors, was approved in October. It enhances the body’s own ability to lower blood sugar levels. Novartis is seeking FDA approval for its own DPP-4 inhibitor, Galvus, but an FDA request for more data has delayed launch.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions